ArticleWorld journal of hepatology2009
Future perspectives on the treatment of hepatocellular carcinoma with cisplatin.
Article in World journal of hepatology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Trial
- Protective effects ofVeterinary world · 2026Article
- Protective effect of abietic acid nanoparticles synthesized by gamma-irradiation against cisplatin-induced renal injury in mice: a promising novel natural nano-drug.Molecular biology reports · 2025Article
- A rat-based preclinical platform facilitating transcatheter hepatic arterial infusion in immunodeficient rats with liver xenografts of patient-derived pancreatic ductal adenocarcinoma.Scientific reports · 2024Article
- Interfering with lipid metabolism through targeting CES1 sensitizes hepatocellular carcinoma for chemotherapy.JCI insight · 2023Article
- The pivotal role of EMT-related noncoding RNAs regulatory axes in hepatocellular carcinoma.Frontiers in pharmacology · 2023Review
- The AntioxidantAntioxidants (Basel, Switzerland) · 2021Article
- Curcumin nanoparticles ameliorate hepatotoxicity and nephrotoxicity induced by cisplatin in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2020Article
- Cisplatin and farnesol co-encapsulated PLGA nano-particles demonstrate enhanced anti-cancer potential against hepatocellular carcinoma cells in vitro.Molecular biology reports · 2020Article
- Morin Hydrate Reverses Cisplatin Resistance by Impairing PARP1/HMGB1-Dependent Autophagy in Hepatocellular Carcinoma.Cancers · 2019Article
- RMP/URI inhibits both intrinsic and extrinsic apoptosis through different signaling pathways.International journal of biological sciences · 2019Article
- Effect of double platinum agents, combination of miriplatin-transarterial oily chemoembolization and cisplatin-hepatic arterial infusion chemotherapy, in patients with hepatocellular carcinoma: Report of two cases.World journal of clinical cases · 2017Article
- Protein phosphatase 2A-B55δ enhances chemotherapy sensitivity of human hepatocellular carcinoma under the regulation of microRNA-133b.Journal of experimental & clinical cancer research : CR · 2016Article
- The Ethanolic Extract of Taiwanofungus camphoratus (Antrodia camphorata) Induces Cell Cycle Arrest and Enhances Cytotoxicity of Cisplatin and Doxorubicin on Human Hepatocellular Carcinoma Cells.BioMed research international · 2015Article
- Article
- Strategy for improving survival and reducing recurrence of HCV-related hepatocellular carcinoma.World journal of gastroenterology · 2013Review
- Fermented wheat germ extract induced cell death and enhanced cytotoxicity of Cisplatin and 5-Fluorouracil on human hepatocellular carcinoma cells.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- Phase I study of miriplatin combined with transarterial chemotherapy using CDDP powder in patients with hepatocellular carcinoma.BMC gastroenterology · 2012Article
- Comparison of the efficacy of transcatheter arterial chemoembolization and sorafenib for advanced hepatocellular carcinoma.Experimental and therapeutic medicine · 2012Article
- Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan.Cancers · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the commonest primary liver malignancy. Its incidence is increasing worldwide. Surgery, including transplantation resection, is currently the most effective treatment for HCC. However, recurrence rates are high and long-term survival is poor. Conventional cytotoxic chemotherapy has not provided clinical benefit or prolonged survival for patients with advanced HCC. Cisplatin (CDDP) is a key drug for the standard regimens of various cancers in the respiratory, digestive and genitourinary organs. Recently, several encouraging results have been shown in using CDDP in the treatment of advanced HCC patients. This review examines current knowledge regarding the chemotherapeutic potential of CDDP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.